Yumanity Therapeutics (Yumanity Therapeutics) Equity-to-Asset : 0.57 (As of Sep. 2022)

View and export this data going back to 2020. Start your Free Trial

What is Yumanity Therapeutics Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Yumanity Therapeutics's Total Stockholders Equity for the quarter that ended in Sep. 2022 was $5.48 Mil. Yumanity Therapeutics's Total Assets for the quarter that ended in Sep. 2022 was $9.58 Mil. Therefore, Yumanity Therapeutics's Equity to Asset Ratio for the quarter that ended in Sep. 2022 was 0.57.

The historical rank and industry rank for Yumanity Therapeutics's Equity-to-Asset or its related term are showing as below:

YMTX's Equity-to-Asset is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.66
* Ranked among companies with meaningful Equity-to-Asset only.

Yumanity Therapeutics Equity-to-Asset Historical Data

The historical data trend for Yumanity Therapeutics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Yumanity Therapeutics Equity-to-Asset Chart

Yumanity Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Equity-to-Asset

-5.22

0.49

0.37

Yumanity Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Equity-to-Asset	Get a 7-Day Free Trial							0.47	0.37	0.37	0.51	0.57

Competitive Comparison of Yumanity Therapeutics's Equity-to-Asset

For the Biotechnology subindustry, Yumanity Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Yumanity Therapeutics's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Yumanity Therapeutics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Yumanity Therapeutics's Equity-to-Asset falls into.

Yumanity Therapeutics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Yumanity Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2021 is calculated as

Equity to Asset (A: Dec. 2021 )	=	Total Stockholders Equity	/	Total Assets
	=	23.497	/	62.932
	=	0.37

Yumanity Therapeutics's Equity to Asset Ratio for the quarter that ended in Sep. 2022 is calculated as

Equity to Asset (Q: Sep. 2022 )	=	Total Stockholders Equity	/	Total Assets
	=	5.476	/	9.579
	=	0.57

Yumanity Therapeutics (NAS:YMTX) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Yumanity Therapeutics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Yumanity Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Yumanity Therapeutics (Yumanity Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Yumanity Therapeutics Inc (NAS:YMTX) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

40 Guest Street, Suite 4410, Boston, MA, USA, 02135

Website

https://www.yumanity.com

Yumanity Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases. The company's lead program, YTX-7739, is in phase 1 clinical development for Parkinson's disease.

Executives

Shawn Iadonato	director, officer: Chief Executive Officer	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Craig W. Philips	officer: President	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Marion R Foote	director	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Raymond J. Bartoszek	director	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Keith Baker	officer: Chief Financial Officer	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Pauline Kenny	officer: General Counsel	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Thierry Guillaudeux	officer: Chief Scientific Officer	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Richard Peters	director, officer: President & CEO	MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
Devin Whittemore Smith	officer: SVP and General Counsel	C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Marie Epstein	officer: Principal Accounting Officer	C/O YUMANITY THERAPEUTICS, INC., 40 GUEST STREET, SUITE 4410, BOSTON MA 02135
Michael D Wyzga	officer: See Remarks	C/O YUMANITY, INC., 40 GUEST STREET, SUITE 4410, BOSTON MA 02135
Paulash Mohsen	officer: Chief Business Officer	C/O YUMANITY THERAPEUTICS, INC., 40 GUESS STREET SUITE 4410, BOSTON MA 02135
Kimberlee C Drapkin	director	PREDIX PHARMACEUTICALS HOLDINGS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421
Ajay Verma	officer: EVP, Head of R&D	C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
N Anthony Coles	director, officer: Executive Chair	MORRIS CORP. CENTER I; BLDG. B; 4TH FLR., 300 INTERPACE PARKWAY, PARSIPPANY NJ 07054